UCL quad and portico

Why partner with UCL Ventures

A trusted gateway to UCL’s most compelling investment opportunities

30+

years of experience

£4.5bn

capital raised since 2016

18

therapeutics in pipeline

1400+

patents files since 1993

Why partner with us?

award icon

One of the UK’s few self-sufficient, self-funding university commercialisation partners.

cash notes icon

Our spinout ventures raised have £3.06 billion in external investment since 2020.

graph icon

Five spinouts made their IPO on NASDAQ and we have multiple high-value exits.

atom icon

Our unique Portico Ventures model helps rapidly set up tech spinouts in fast-moving sectors.

Portfolio highlights

Trace Neuroscience
ALS patient in wheelchair - Trace Neuroscience

Neurology & brain sciences

Trace Neuroscience

Genomic medicine for neurodegenerative diseases, with a focus on ALS.

Oriole Networks
Man looking at internet modems

Energy & cleantech

Oriole Networks

Photonics accelerating AI and ML in a low-carbon world.

MeiraGTx
close up of blue eye

Drug discovery

MeiraGTx

Clinical-stage gene therapy company with broad pipeline.

Interested in partnering with us?

With a track record of success and connection to one of the world's leading universities, UCL Ventures is a trusted partner.

Get in touch